Press release

Showing 15 posts of 581 posts found.

Treatment for rare, paediatric growth hormone deficiency recommended by NICE for use on the NHS

December 22, 2022
Medical Communications

Walton Oaks, 22 December 2022 – Pfizer Ltd today announces that the National Institute for Health and Care Excellence (NICE) …

Innovative Antibody Discovered by RQ Bio Enters Clinic as Part of Antibody Combination Within 12 Months of Discovery

December 21, 2022
Medical Communications

LONDON, UK, 21st December 2022 — RQ Bio announces that the first of its discovered monoclonal antibodies to prevent COVID-19 …

Sosei Heptares’ Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity

December 21, 2022
Business Services

Tokyo, Japan and Cambridge, UK, 21 December 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …

Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme

December 21, 2022
Business Services

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that it …

NICE EXTENDS USE OF ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) TO EARLIER IN THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER

December 20, 2022
Business Services

Uxbridge and London, UK – (20 December 2022) – Daiichi Sankyo UK Limited and AstraZeneca UK Limited today welcome the …

Psoriasis community comes together and calls for collective action to help improve the lives of people with psoriasis

December 19, 2022
Business Services

Slough, UK, 15 December 2022 – UCB, a global biopharmaceutical company, has announced results from the Epicensus programme, published in …

Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases

December 19, 2022
Business Services

Tokyo, Japan and Cambridge, UK, 16 December 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) announces it has entered …

Alchemab Therapeutics and Medicines Discovery Catapult awarded £1.7 million grant from Innovate UK to accelerate development of disease-modifying therapy for Huntington’s Disease

December 19, 2022
Business Services

Cambridge, UK. December 16 2022 – Alchemab Therapeutics, a biotechnology company unlocking new therapies from within the immune system, today …

FlyPharma Conference Middle East: New location announced

December 14, 2022
Business Services

FlyPharma Conferences are pleased to announce an exciting new addition to its event portfolio: FlyPharma Middle East. Taking place in …

PPAs – Ready to make a long-term commitment to zero carbon?

December 14, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Energy, sustainability

As an industry that consumes a large amount of energy, the pressure is on for the pharmaceutical sector to achieve …

Interactions with the Agencies During Drug Development

April 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cambridge, NDA, drug development

 NDA would like to invite you to join  Professor Steffen Thirstrup, Director NDA Advisory Board, formerly Division Head at the Danish Medicines …

Woodley Equipment Company Acquires Blinded Diagnostics

December 11, 2018
Research and Development POCT, Point of Care Testing, clinical research, clinical trials, point-of-care testing

HORWICH, BOLTON Dec1 2018: Woodley Equipment Company Inc, a leading global supplier of rental equipment for use in Clinical Trials …

The Gateway to Local Adoption Series

Latest content